| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 30 | 2024 | 4139 | 2.940 |
Why?
|
| Carcinoma, Squamous Cell | 32 | 2024 | 5585 | 2.380 |
Why?
|
| src-Family Kinases | 16 | 2017 | 487 | 2.240 |
Why?
|
| Protein Kinase Inhibitors | 28 | 2021 | 4958 | 2.090 |
Why?
|
| Thiazoles | 10 | 2012 | 723 | 1.920 |
Why?
|
| Papillomavirus Infections | 10 | 2024 | 999 | 1.790 |
Why?
|
| Lung Neoplasms | 33 | 2021 | 12019 | 1.680 |
Why?
|
| Pyrimidines | 19 | 2017 | 3662 | 1.580 |
Why?
|
| Pteridines | 5 | 2019 | 35 | 1.560 |
Why?
|
| Cell Cycle Proteins | 8 | 2022 | 2115 | 1.440 |
Why?
|
| Dasatinib | 13 | 2017 | 881 | 1.410 |
Why?
|
| ErbB Receptors | 17 | 2018 | 2376 | 1.340 |
Why?
|
| Oropharyngeal Neoplasms | 14 | 2024 | 1161 | 1.320 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 398 | 1.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2019 | 5566 | 1.250 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2019 | 2616 | 1.220 |
Why?
|
| Apoptosis | 23 | 2022 | 7740 | 1.180 |
Why?
|
| Receptor, Notch1 | 4 | 2022 | 216 | 1.130 |
Why?
|
| Antineoplastic Agents | 28 | 2023 | 14613 | 1.120 |
Why?
|
| STAT3 Transcription Factor | 7 | 2017 | 1135 | 0.970 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1707 | 0.930 |
Why?
|
| Cell Line, Tumor | 31 | 2023 | 14824 | 0.900 |
Why?
|
| Cell Proliferation | 20 | 2022 | 7230 | 0.890 |
Why?
|
| Camptothecin | 5 | 2010 | 540 | 0.870 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2019 | 427 | 0.870 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2022 | 84 | 0.820 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 148 | 0.790 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2017 | 1837 | 0.790 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 172 | 0.730 |
Why?
|
| Receptor, EphA2 | 3 | 2013 | 138 | 0.720 |
Why?
|
| Professional-Family Relations | 1 | 2021 | 131 | 0.700 |
Why?
|
| Mutation | 16 | 2021 | 15900 | 0.700 |
Why?
|
| Goals | 1 | 2021 | 187 | 0.690 |
Why?
|
| Tumor Burden | 6 | 2018 | 2031 | 0.690 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 3911 | 0.670 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 2 | 2011 | 99 | 0.660 |
Why?
|
| Thoracic Cavity | 1 | 2018 | 10 | 0.640 |
Why?
|
| Papillomaviridae | 8 | 2024 | 636 | 0.630 |
Why?
|
| Vimentin | 1 | 2019 | 255 | 0.610 |
Why?
|
| X-Ray Microtomography | 1 | 2018 | 136 | 0.600 |
Why?
|
| Aurora Kinase A | 2 | 2018 | 210 | 0.590 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 1327 | 0.580 |
Why?
|
| Carcinoma, Small Cell | 3 | 2006 | 427 | 0.580 |
Why?
|
| LIM Domain Proteins | 1 | 2017 | 103 | 0.550 |
Why?
|
| Janus Kinases | 3 | 2016 | 175 | 0.550 |
Why?
|
| ras Proteins | 3 | 2017 | 804 | 0.550 |
Why?
|
| Humans | 101 | 2024 | 270026 | 0.540 |
Why?
|
| Terminal Care | 1 | 2021 | 465 | 0.530 |
Why?
|
| Maximum Tolerated Dose | 6 | 2016 | 1320 | 0.530 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2017 | 169 | 0.520 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 734 | 0.510 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2020 | 1002 | 0.510 |
Why?
|
| Janus Kinase 2 | 2 | 2011 | 754 | 0.510 |
Why?
|
| Quinazolines | 3 | 2012 | 956 | 0.510 |
Why?
|
| raf Kinases | 1 | 2015 | 80 | 0.510 |
Why?
|
| Mouth Neoplasms | 4 | 2017 | 734 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 9035 | 0.500 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2015 | 84 | 0.500 |
Why?
|
| Cell Movement | 4 | 2012 | 2457 | 0.500 |
Why?
|
| Mice, Nude | 8 | 2021 | 4329 | 0.490 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 784 | 0.490 |
Why?
|
| Cisplatin | 11 | 2023 | 2496 | 0.480 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2015 | 668 | 0.470 |
Why?
|
| Cell Cycle | 6 | 2018 | 2136 | 0.470 |
Why?
|
| Cell Survival | 7 | 2016 | 3055 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 1900 | 0.450 |
Why?
|
| Cellular Senescence | 1 | 2016 | 388 | 0.440 |
Why?
|
| Signal Transduction | 15 | 2020 | 12083 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 5062 | 0.440 |
Why?
|
| Taxoids | 3 | 2016 | 1016 | 0.430 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 1563 | 0.420 |
Why?
|
| Animals | 30 | 2021 | 61707 | 0.420 |
Why?
|
| Receptor, EphA4 | 1 | 2012 | 9 | 0.420 |
Why?
|
| Ephrins | 1 | 2012 | 11 | 0.420 |
Why?
|
| Drug Interactions | 3 | 2015 | 574 | 0.420 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2018 | 417 | 0.410 |
Why?
|
| Blotting, Western | 9 | 2016 | 3585 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 16640 | 0.410 |
Why?
|
| Piperazines | 3 | 2006 | 2145 | 0.410 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2005 | 340 | 0.400 |
Why?
|
| Etoposide | 4 | 2010 | 905 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2023 | 5403 | 0.390 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 62 | 0.390 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2017 | 252 | 0.390 |
Why?
|
| Pyrazoles | 7 | 2018 | 1539 | 0.380 |
Why?
|
| Mice | 23 | 2021 | 35461 | 0.370 |
Why?
|
| Neoplasms | 10 | 2021 | 15900 | 0.370 |
Why?
|
| STAT5 Transcription Factor | 1 | 2011 | 226 | 0.360 |
Why?
|
| DNA Repair | 2 | 2016 | 1910 | 0.360 |
Why?
|
| Ketoconazole | 1 | 2010 | 36 | 0.360 |
Why?
|
| Phosphorylation | 10 | 2019 | 4937 | 0.350 |
Why?
|
| Human papillomavirus 16 | 3 | 2022 | 255 | 0.350 |
Why?
|
| STAT Transcription Factors | 1 | 2010 | 80 | 0.350 |
Why?
|
| Enzyme Activation | 8 | 2017 | 1800 | 0.340 |
Why?
|
| Palliative Care | 1 | 2021 | 2173 | 0.330 |
Why?
|
| TYK2 Kinase | 1 | 2009 | 12 | 0.330 |
Why?
|
| Eyelashes | 1 | 2008 | 4 | 0.320 |
Why?
|
| Hypertrichosis | 1 | 2008 | 6 | 0.320 |
Why?
|
| Drug Therapy | 1 | 2009 | 204 | 0.320 |
Why?
|
| Drug Synergism | 5 | 2017 | 1359 | 0.320 |
Why?
|
| DNA Damage | 2 | 2017 | 1981 | 0.320 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2008 | 35 | 0.320 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2021 | 273 | 0.320 |
Why?
|
| Female | 46 | 2024 | 148487 | 0.300 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3343 | 0.300 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 10694 | 0.300 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 485 | 0.300 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 1554 | 0.290 |
Why?
|
| Carboplatin | 4 | 2015 | 879 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 6 | 2012 | 4043 | 0.290 |
Why?
|
| Disease Models, Animal | 7 | 2021 | 7342 | 0.280 |
Why?
|
| Anaphase | 2 | 2017 | 54 | 0.280 |
Why?
|
| Male | 46 | 2024 | 127915 | 0.270 |
Why?
|
| Inhibitory Concentration 50 | 5 | 2015 | 285 | 0.250 |
Why?
|
| Thiophenes | 2 | 2017 | 147 | 0.250 |
Why?
|
| Immunoprecipitation | 4 | 2013 | 589 | 0.250 |
Why?
|
| Aged | 33 | 2024 | 73128 | 0.250 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 5000 | 0.250 |
Why?
|
| Retinoblastoma Protein | 2 | 2022 | 339 | 0.250 |
Why?
|
| Middle Aged | 35 | 2024 | 90031 | 0.240 |
Why?
|
| S Phase | 3 | 2017 | 288 | 0.240 |
Why?
|
| Thyroid Neoplasms | 3 | 2021 | 1876 | 0.240 |
Why?
|
| Molecular Targeted Therapy | 3 | 2022 | 2390 | 0.230 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 3524 | 0.230 |
Why?
|
| Benzamides | 4 | 2018 | 1878 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 10382 | 0.230 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 230 | 0.230 |
Why?
|
| Epidermal Growth Factor | 1 | 2005 | 439 | 0.230 |
Why?
|
| Dinoprostone | 1 | 2004 | 219 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2007 | 671 | 0.220 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2024 | 89 | 0.220 |
Why?
|
| Phenotype | 3 | 2021 | 6485 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1899 | 0.220 |
Why?
|
| Neoplasm Staging | 11 | 2021 | 13994 | 0.220 |
Why?
|
| Time Factors | 8 | 2020 | 12953 | 0.220 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4887 | 0.220 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 64 | 0.210 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 69 | 0.210 |
Why?
|
| Drug Design | 3 | 2017 | 371 | 0.210 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 86 | 0.210 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 67 | 0.210 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 485 | 0.210 |
Why?
|
| Aurora Kinases | 1 | 2022 | 193 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2015 | 437 | 0.200 |
Why?
|
| Pyrazines | 2 | 2016 | 510 | 0.200 |
Why?
|
| Disease-Free Survival | 8 | 2016 | 10258 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2007 | 558 | 0.200 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 485 | 0.200 |
Why?
|
| RNA Interference | 2 | 2017 | 1384 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 4 | 2013 | 1183 | 0.200 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2021 | 39 | 0.190 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 98 | 0.190 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 7883 | 0.190 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 97 | 0.190 |
Why?
|
| Tonsillar Neoplasms | 1 | 2021 | 81 | 0.190 |
Why?
|
| Enteral Nutrition | 1 | 2024 | 346 | 0.190 |
Why?
|
| Smoking | 2 | 2016 | 2548 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 1077 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1334 | 0.180 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 30923 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2021 | 187 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 133 | 0.180 |
Why?
|
| Pyrimidinones | 3 | 2017 | 318 | 0.180 |
Why?
|
| Imidazoles | 2 | 2018 | 1056 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2017 | 1400 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 1942 | 0.180 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 412 | 0.180 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 205 | 0.170 |
Why?
|
| Phosphoproteins | 3 | 2017 | 1136 | 0.170 |
Why?
|
| Galactosyltransferases | 1 | 1999 | 10 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2020 | 2161 | 0.170 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2017 | 78 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2020 | 33692 | 0.170 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 433 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 355 | 0.170 |
Why?
|
| Survival Analysis | 7 | 2016 | 9288 | 0.170 |
Why?
|
| Immunotherapy | 3 | 2022 | 3551 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2021 | 302 | 0.170 |
Why?
|
| Orbit Evisceration | 1 | 2019 | 47 | 0.160 |
Why?
|
| Prognosis | 12 | 2024 | 22451 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2019 | 1867 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 470 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 6 | 2021 | 5756 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2020 | 1272 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 128 | 0.160 |
Why?
|
| Disease Progression | 5 | 2020 | 6840 | 0.160 |
Why?
|
| Robotic Surgical Procedures | 2 | 2024 | 532 | 0.150 |
Why?
|
| Pyridines | 2 | 2019 | 1310 | 0.150 |
Why?
|
| Carcinoma | 2 | 2014 | 2607 | 0.150 |
Why?
|
| Streptococcus agalactiae | 1 | 1999 | 113 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 1276 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 174 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 165 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2021 | 526 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2017 | 271 | 0.150 |
Why?
|
| Gene Expression | 2 | 2019 | 3630 | 0.150 |
Why?
|
| Hydroxamic Acids | 2 | 2017 | 454 | 0.150 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 559 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.150 |
Why?
|
| Adult | 22 | 2020 | 81692 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 211 | 0.150 |
Why?
|
| Eyelid Neoplasms | 1 | 2019 | 193 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2072 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3653 | 0.140 |
Why?
|
| Imatinib Mesylate | 3 | 2006 | 1690 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 5137 | 0.140 |
Why?
|
| Anilides | 1 | 2019 | 294 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3599 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6253 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 130 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2016 | 83 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 267 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3437 | 0.140 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 64 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 498 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2018 | 729 | 0.140 |
Why?
|
| Gene Editing | 1 | 2019 | 229 | 0.130 |
Why?
|
| Quinolines | 2 | 2018 | 400 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 112 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 286 | 0.130 |
Why?
|
| Heterografts | 2 | 2015 | 739 | 0.130 |
Why?
|
| Comet Assay | 1 | 2016 | 57 | 0.130 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 197 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 834 | 0.130 |
Why?
|
| Streptococcal Infections | 1 | 1999 | 317 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 135 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 199 | 0.130 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 188 | 0.130 |
Why?
|
| Registries | 1 | 2024 | 2205 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 210 | 0.130 |
Why?
|
| Smad4 Protein | 1 | 2017 | 201 | 0.130 |
Why?
|
| Genes, ras | 2 | 2009 | 679 | 0.130 |
Why?
|
| Gentian Violet | 2 | 2005 | 23 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2015 | 85 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 299 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 356 | 0.130 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2006 | 153 | 0.130 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 352 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 5225 | 0.120 |
Why?
|
| Adenosine | 1 | 2017 | 296 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 123 | 0.120 |
Why?
|
| Survival Rate | 7 | 2021 | 12508 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 229 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2015 | 232 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 1999 | 343 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 537 | 0.120 |
Why?
|
| Tissue Array Analysis | 3 | 2013 | 757 | 0.110 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 288 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1105 | 0.110 |
Why?
|
| Integrin beta3 | 1 | 2013 | 46 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 4209 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 744 | 0.110 |
Why?
|
| Bacteremia | 1 | 1999 | 721 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 562 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 2196 | 0.110 |
Why?
|
| Occludin | 1 | 2012 | 26 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 15172 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1654 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 678 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1094 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2013 | 166 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1603 | 0.100 |
Why?
|
| Cytokines | 3 | 2010 | 2810 | 0.100 |
Why?
|
| Retrospective Studies | 12 | 2024 | 39738 | 0.100 |
Why?
|
| Software | 2 | 2018 | 1356 | 0.100 |
Why?
|
| Transfection | 1 | 2017 | 3115 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2016 | 897 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 351 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4955 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2016 | 6752 | 0.090 |
Why?
|
| Deglutition | 2 | 2022 | 187 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 618 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6367 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 1512 | 0.090 |
Why?
|
| Cell Line | 1 | 2018 | 5334 | 0.090 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2010 | 27 | 0.090 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 49 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 1013 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2013 | 826 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2012 | 163 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 86 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 517 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2010 | 178 | 0.080 |
Why?
|
| Precancerous Conditions | 3 | 2010 | 1033 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2010 | 242 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 637 | 0.080 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 105 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 2014 | 416 | 0.080 |
Why?
|
| Drug Antagonism | 1 | 2008 | 33 | 0.080 |
Why?
|
| Genotype | 1 | 2017 | 4249 | 0.080 |
Why?
|
| Neutropenia | 2 | 2010 | 1006 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 234 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2122 | 0.080 |
Why?
|
| Biological Transport | 1 | 2009 | 623 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 4318 | 0.080 |
Why?
|
| Exons | 2 | 2013 | 1381 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1197 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 499 | 0.070 |
Why?
|
| Sulfones | 1 | 2008 | 145 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2010 | 823 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 4462 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2012 | 1711 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 5099 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2012 | 1193 | 0.070 |
Why?
|
| Biomarkers | 1 | 2018 | 5046 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1742 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 392 | 0.070 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2005 | 19 | 0.070 |
Why?
|
| Trypan Blue | 1 | 2005 | 15 | 0.070 |
Why?
|
| Diarrhea | 1 | 2009 | 712 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 773 | 0.070 |
Why?
|
| Paxillin | 1 | 2005 | 32 | 0.060 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2005 | 27 | 0.060 |
Why?
|
| Stem Cell Factor | 1 | 2005 | 83 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2010 | 1042 | 0.060 |
Why?
|
| Laminin | 1 | 2005 | 209 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 5309 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 770 | 0.060 |
Why?
|
| Eicosanoids | 1 | 2004 | 29 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 655 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 894 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 687 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1948 | 0.060 |
Why?
|
| Pyridones | 1 | 2007 | 360 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 278 | 0.060 |
Why?
|
| G1 Phase | 1 | 2005 | 305 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 120 | 0.060 |
Why?
|
| Denmark | 1 | 2024 | 55 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2010 | 1145 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2004 | 161 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2326 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2004 | 110 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1557 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 3288 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 1159 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 484 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 635 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 9039 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 771 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 568 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2020 | 2316 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2009 | 2417 | 0.050 |
Why?
|
| Texas | 2 | 2012 | 6430 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 341 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 3993 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 617 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6204 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 118 | 0.050 |
Why?
|
| Collagen | 1 | 2005 | 710 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4103 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1026 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 494 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 657 | 0.050 |
Why?
|
| Melanoma | 1 | 1999 | 5594 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2021 | 69 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3070 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2196 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 128 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 2646 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 3999 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 81 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1989 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 9464 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5250 | 0.050 |
Why?
|
| Young Adult | 5 | 2018 | 22134 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1435 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 514 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 323 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3842 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 6182 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 324 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 7632 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 154 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1999 | 349 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 451 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 724 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 847 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 253 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 1119 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 1999 | 303 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3030 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1581 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 2269 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2018 | 73 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2021 | 2027 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 525 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 13378 | 0.040 |
Why?
|
| Platinum | 1 | 2018 | 142 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 323 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1999 | 519 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 670 | 0.040 |
Why?
|
| Immunoblotting | 1 | 1999 | 892 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 164 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 778 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 191 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 1568 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 1211 | 0.040 |
Why?
|
| Centrosome | 1 | 2017 | 106 | 0.040 |
Why?
|
| Quality of Life | 2 | 2022 | 4772 | 0.030 |
Why?
|
| CCCTC-Binding Factor | 1 | 2016 | 35 | 0.030 |
Why?
|
| Indolizines | 1 | 2016 | 46 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 693 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 97 | 0.030 |
Why?
|
| Placebos | 1 | 2017 | 443 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 3353 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Purines | 1 | 2017 | 271 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 141 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2016 | 164 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3398 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 506 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2018 | 743 | 0.030 |
Why?
|
| Risk Factors | 3 | 2020 | 17824 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 76 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 909 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2843 | 0.030 |
Why?
|
| Tonsillectomy | 1 | 2016 | 119 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7779 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 622 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2016 | 364 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 2926 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 474 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 16182 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 530 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 728 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 677 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2358 | 0.030 |
Why?
|
| Cell Division | 1 | 2016 | 2651 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 1542 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7892 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 316 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2012 | 294 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2586 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5449 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2014 | 490 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2014 | 358 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2015 | 1140 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 1824 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 554 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 566 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Adolescent | 2 | 2014 | 32646 | 0.020 |
Why?
|
| Leukoplakia, Oral | 1 | 2010 | 71 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 788 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4956 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 191 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 907 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2760 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2007 | 205 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 725 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 3897 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 2089 | 0.010 |
Why?
|
| Precision Medicine | 1 | 2010 | 1207 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1456 | 0.010 |
Why?
|
| Nitriles | 1 | 2007 | 938 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 1338 | 0.010 |
Why?
|
| United States | 1 | 2019 | 15776 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 2101 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2348 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 5693 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 2883 | 0.010 |
Why?
|
| Child | 1 | 2010 | 30466 | 0.010 |
Why?
|